CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 2.49 USD 3.75% Market Closed
Market Cap: 392.3m USD

Wall Street
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 5.61 USD with a low forecast of 3.54 USD and a high forecast of 8.4 USD.

Lowest
Price Target
3.54 USD
42% Upside
Average
Price Target
5.61 USD
125% Upside
Highest
Price Target
8.4 USD
237% Upside
CytomX Therapeutics Inc Competitors:
Price Targets
NGNE
Neurogene Inc
104% Upside
MDGL
Madrigal Pharmaceuticals Inc
39% Upside
IKT
Inhibikase Therapeutics Inc
304% Upside
4BB
4Basebio PLC
73% Upside
RCKT
Rocket Pharmaceuticals Inc
311% Upside
SKYE
Skye Bioscience Inc
316% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
29% Upside

Revenue
Forecast

Revenue Estimate
CytomX Therapeutics Inc

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 32%. The projected CAGR for the next 3 years is -49%.

32%
Past Growth
-49%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-73%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTMX's stock price target?
Price Target
5.61 USD

According to Wall Street analysts, the average 1-year price target for CTMX is 5.61 USD with a low forecast of 3.54 USD and a high forecast of 8.4 USD.

What is CytomX Therapeutics Inc's Revenue forecast?
Projected CAGR
-49%

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 32%. The projected CAGR for the next 3 years is -49%.

Back to Top